Clinical factors were not associated with rSO2 and FTOE, but rSO2 was nearly significantly positively associated with midazolam at day 2 (p=0.05), and negatively with pHCO2 at day 3 (p=0.051).

Conclusions Highest RSO2-values and lowest FTOE-values were seen on day two, suggesting decreased oxygen consumption, possibly as a consequence of midazolam treatment. Even so, treatment with high fIO2 did not lead to high levels of oxygen in brain tissue in most infants.

**Results**

Physical exam, cyanosis in the first 12 hours, tachypnea and/or a severe respiratory distress, systolic murmur on the left border of sternum. ECG: diastolic dysfunction of left ventricular (LV). Chest X-ray: cardiomegaly (all cases). PaO2: low values—all patients. ECHO: enlargement of the right chambers; severe tricuspid regurgitation with the peak velocity 3–4 m/sec; mitral regurgitation (12/41 of cases), left-to-right shunt across foramen ovale and/or ductus arteriosus (30/41 of cases), enlargement of the pulmonary artery and severe pulmonary regurgitation, septal hypertrophy (11/41 of cases); impaired LV relaxation with normal systolic function; congenital heart diseases (7). Repeated ECHO revealed in most of the cases diminished or no right-to-left shunt across ductus arteriosus or foramen ovale correlate with clinical improvement and disappearance of cyanosis.

Conclusions Echocardiographic exam, beside clinical exam and history of the disease, is an important element for the diagnosis and follow up of evolution by the specific treatment applied for PPHN in the newborn with cyanosis and this investigation must be performed early after birth.

**Introduction**

PPHN is treated with inhaled nitric oxide (iNO). A novel ventilator circuit connector (NVCC, AFECTAIR®, Discovery Laboratories, Inc., Warrington, PA) has been developed to simplify the delivery of aerosols to patients receiving ventilatory support. We hypothesized that use of the NVCC for iNO delivery would substantially reduce NO consumption.

**Aim**

To compare the NVCC with the SoC in the delivery of iNO under simulated neonatal ventilator conditions.

**Material and Methods**

A pediatric/neonatal test system with Babylog® VN-500 with various inspiratory pressures, test lung, and ASL-5000 lung simulator were used. For SoC measurements, using a standard wye connector, the iNO was delivered per the manufacturer’s instructions. With the NVCC, iNO was administered by introducing the NO via a tube attached directly to the NVCC. NO concentrations were measured with a NOxBOX®+ analyzer and NO flow was recorded by Electronic Nitric Oxide flow controller and titrated to 20 ppm at the patient interface.

**Results**

Compared with SoC, there was a 2 to 3 fold decrease in NO flow requirements to achieve desired iNO concentration with the NVCC. The delivery of O2 was not different between the study conditions. NO levels were slightly higher for the NVCC group, but never higher than 1.15 ppm.

**Conclusion**

The NVCC significantly decreased the NO flow required for targeted delivery of 20 ppm. The NVCC allows for simplified therapeutic gas delivery with reduced NO utilization. These results warrant further study of NVCC on compatibility assessment with various modes of ventilation and delivery of other medical gases.
Subject & Method A hospital based, retrospective case-review study was carried out in Pediatric department, Al-Adan Hospital, State Of Kuwait. The file of all patients less than 12 year age, and for whom CT lung was performed during the last five years (2000–2005) were reviewed.

Results Thirty patients for whom CT lung was performed were reviewed. The main indication for requesting chest CT was persistent abnormal CX-ray findings (90%) in a patient with uncontrolled wheeze and/or recurrent pneumonia. Findings of chest CT was the same as CX-ray findings (80%) and more specific +/- new diagnosis (20%). Results of chest CT influenced medical treatment only in seven of the cases (23%) and led to surgical intervention in two patients (0.06%), (tornia, cystic adenomatoidmalformation).

Conclusion Our data demonstrate that the result of CT lung in children doesn’t alter clinical decision and management of most of the cases. Therefore CT lung should be requested mainly for the high risk patients, preferably by a pulmonologist and after discussing the chest x-ray findings with a radiologist.

1709 ESTIMATION OF NEONATAL ENDOTRACHEAL TUBE RESISTANCE BY WATER MANOMETER
doi:10.1136/archdischild-2012-302724.1709

P Mallya, P Webb, S Gupta. 1Paediatrics and Neonatal Medicine, University Hospital of North Tees, Stockton; 2Medical Physics, James Cook University Hospital, Middlesbrough; University of Durham, Durham, UK

Background The loss of pressures at the distal end of ET tube can be affected by the size and diameter of the ET tube and the flow rates.

Aim To study in vitro the pressure drop using varying sizes of ET tubes commonly used in preterm infants at different lengths, flow rates using different gases.

Methods We used Portex tubes for this in-vitro study. A water manometer (scale 0–300mm) was used to measure the pressure drop across ET tube. We used two different lengths (7 and 14cms); different sizes (2.5; 3.0; 3.5 and 4.0mm), different flow rates (4 to 11 litres/min) and two different gases (medical air and 100% oxygen) to assess the resistance across the ET tube. SPSS version 17® was used for statistical analysis. Data presented as mean(SD).

Results
1. There was no difference in the pressure drop at lengths of 7cms and 14cms respectively using air [120.6 (66.12) vs.127.3 (60.74)cms H2O; p=0.297], but with 100% oxygen there was statistically significant increase at 14cm compared to 7cm length [146.73 (72.94) vs. 130.48 (72.94)cms H2O; p=0.015 at similar flow rates.
2. At all flow rates there was no difference in pressure drop at different tube diameters using air or 100% oxygen.
3. There was a statistically significant (p<0.05) increase in pressure drop at flow rates increasing from 4 to 11 litres/min.

Abstract 1709 Table 1 Comparison of pressure drop with air and oxygen using air or oxygen at different flow rates and with varying ETtube sizes.

1710 SEROPREVALENCE OF CHLAMYDIA PNEUMONIAE AND MYCOPLASMA PNEUMONIAE IN CHILDREN WITH CHRONIC COUGH
doi:10.1136/archdischild-2012-302724.1710

S Asilsoy, E Bayram, ‘D Can. 1Pediatric Allergy, Başkent University, Adana; 2Dokuz Eylül University; 3Dr Behcet Uz Çocuk Hastanesi, Izmir, Turkey

Background Chronic cough is one of the most common symptoms in children. Postinfectious etiologies plays an important role in chronic cough in childhood. The pathogenesis of the postinfectious cough may be related persistent inflammation and the epithelial damage in the upper and lower airways, with or without transient airway hyperresponsiveness. We evaluated Mycoplasma pneumoniae and Chlamydia pneumoniae serology and treatment in children referred with chronic cough.

Methods This study enrolled 41 children between 6 and 14 years of age having cough which lasted than 4 weeks. They were evaluated according to American College of Chest Physicians guideline. Pulmonary function test and chest x-ray were performed to all patients. M. pneumoniae and C. pneumoniae serologies were analyzed by ELISA. They were reevaluated with 2 to 4 weeks intervals until cough disappeared.

Results The study included 41 children, 27 of whom were female (65.9%). The mean age was 8.00±1.96 year. M. pneumoniae IgM positivity was found in 17.07% (7/41) of patients, C. pneumoniae IgM positivity in 2.85% (1/35), M. pneumoniae IgM and/or IgG positivity in 41.46% (17/41), C. pneumoniae IgM and/or IgG positivity in 25.7% (9/35). Symptoms were not improved along with clarithromycine treatment so inhaled/nasal steroids were added according to diagnosis.

Conclusion In children with chronic cough, aged 6 to 14 years old, M. pneumoniae and C. pneumoniae play important roles in the etiology. Clarithromycin alone may not be enough in the treatment of chronic cough due to these agents, so the treatment should be planned according to clinical findings.

1711 THE RELATIONSHIP BETWEEN THE FIRST EPISODE OF WHEEZING AND MATRIX METALLOPROTEINASES-9 AND –2 AND TIMP-1 LEVELS IN PRETERM INFANTS
doi:10.1136/archdischild-2012-302724.1711

RG Sezer, A Bozyakut, IA Tanju, G Aydemir, LP Sener, S Hira, O Ozcan. 1Department of Pediatrics, Zeyneb Kamit Maternity and Children’s Disease Training and Research State Hospital; 2Department of Pediatrics; 3Department of Biochemistry, GAiTa Teaching Hospital, Istanbul, Turkey

Background Elevated concentrations of matrix metalloproteinasenes (MMP) have been associated with neonatal morbidity. There are no data on the serum levels of MMP-2, MMP-9, tissue inhibitors of matrix metalloproteinase (TIMP-1) from preterm infants recovering from these morbidities. We aimed to compare MMP-2, MMP-9, and TIMP-1 levels in preterm and term infants hospitalized with their first episode of wheezing.

Methods We prospectively evaluated 18 preterm infants with a history of chronic lung disease, respiratory distress syndrome and 14 age- and sex- matched term infants who were admitted for a first episode of wheezing. We quantified total serum concentrations of MMP-2, MMP-9, and TIMP-1 to assess whether these serum markers levels were associated with wheezing with a history of oxygen therapy during the neonatal period.

Results Upon hospitalization for the first episode of wheezing, MMP-2 and TIMP-1 levels were higher in preterm infants than in term infants.